[Double-blind study on the antispastic effect of beta-94-chlorphenyl)-gamma aminobutyric acid (CIBA) in multiple sclerosis].
D000613:Aminobutyrates / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009132:Muscles / Q000627:therapeutic use*; D010919:Placebos; D013035:Spasm / Q000188:drug therapy
D000613:Aminobutyrates; D010919:Placebos
Doppeltblindstudie über den antispastischen Effekt von beta-(4-Chlorphenyl)-gamma-aminobuttersäure (CIBA) bei Multipler Sklerose.